Last updated: November 11, 2026
Pentazocine hydrochloride and naloxone hydrochloride is an older oral opioid combination marketed primarily as Talwin NX, typically containing 50 mg of pentazocine hydrochloride and 0.5 mg of naloxone hydrochloride per tablet. The product has limited commercial growth potential because it competes with inexpensive generic opioids, newer abuse-deterrent products, non-opioid analgesics, and increasingly restrictive opioid-prescribing policies. Its active-ingredient, formulation, and method-of-use patent barriers are largely exhausted. Public filings do not disclose a reliable product-level revenue history, so the financial trajectory is best characterized as mature, low-growth, and exposed to continuing volume erosion.
What is naloxone hydrochloride and pentazocine hydrochloride?
The combination is an oral analgesic containing pentazocine, a mixed opioid agonist-antagonist, and naloxone, an opioid antagonist.
| Attribute |
Description |
| Active ingredients |
Pentazocine hydrochloride and naloxone hydrochloride |
| Typical strength |
50 mg pentazocine / 0.5 mg naloxone per tablet |
| Dosage form |
Immediate-release oral tablet |
| Primary use |
Management of moderate to severe pain when an opioid is appropriate |
| Pharmacology |
Pentazocine provides analgesia; naloxone is intended to reduce abuse by injection |
| U.S. regulatory category |
Prescription opioid; federally controlled substance |
| Commercial reference product |
Talwin NX |
| Therapeutic class |
Opioid analgesic |
| Principal commercial risk |
Generic substitution and declining opioid utilization |
Naloxone has low systemic bioavailability when taken orally as directed. If the tablet is crushed and injected, naloxone is intended to antagonize opioid effects and reduce the attractiveness of non-oral abuse. The combination therefore predates current abuse-deterrent technologies but is not equivalent to a modern FDA-labeled abuse-deterrent formulation under the FDA’s abuse-deterrent opioid guidance.[1]
What is the FDA regulatory status of the combination?
The product is an established prescription drug with historical FDA approval under the new drug application pathway. Talwin NX labeling identifies the product as an oral tablet containing pentazocine hydrochloride and naloxone hydrochloride.[2]
The FDA’s regulatory framework has changed materially since the product’s introduction:
- Opioid labeling includes boxed warnings addressing addiction, abuse, misuse, overdose, life-threatening respiratory depression, and neonatal opioid withdrawal.
- Prescribing is subject to federal and state controlled-substance requirements.
- The product is not a medication for opioid use disorder.
- Naloxone in the combination does not convert the product into an overdose-reversal product.
- The product is distinct from standalone naloxone products, including injectable and intranasal formulations used for opioid overdose reversal.
Pentazocine products have historically been placed in Schedule IV under the federal Controlled Substances Act. Scheduling and state-level requirements should be confirmed against current Drug Enforcement Administration and state rules before commercial or distribution decisions.[3]
When does naloxone-pentazocine lose exclusivity?
The combination has no meaningful remaining market exclusivity based on the original active ingredients. Pentazocine was introduced decades ago, and the pentazocine-naloxone combination has been commercially available since the twentieth century. Any original composition, formulation, or product patents would have expired long before the current market period.
Patent and exclusivity position
| Protection category |
Current commercial relevance |
| Pentazocine composition patents |
Expired |
| Naloxone composition patents relevant to the combination |
Expired |
| Original combination patents |
Expired or commercially exhausted |
| Original formulation patents |
Expired |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
No current relevance identified |
| Orphan-drug exclusivity |
Not applicable |
| Reference-product exclusivity |
Expired |
| Modern abuse-deterrent formulation patents |
Not established for the legacy product |
The key commercial barrier is therefore not patent expiry. It is the cost of maintaining an approved controlled-substance product, securing manufacturing capacity, managing regulatory compliance, and obtaining distribution access.
What patents protect naloxone hydrochloride and pentazocine hydrochloride?
No active, high-value U.S. patent estate is generally associated with the legacy 50 mg/0.5 mg immediate-release combination. The relevant intellectual-property assets are more likely to involve:
- Trademarks associated with Talwin or Talwin NX;
- Manufacturing know-how;
- Supplier qualification;
- Controlled-substance production controls;
- Stability data and quality systems;
- Product-specific regulatory filings;
- Distribution contracts;
- Packaging and serialization systems.
These assets may create operational friction for a new entrant but do not provide patent exclusivity equivalent to a protected new chemical entity or patented extended-release formulation.
Are formulation patents still relevant?
Formulation patents can matter if a manufacturer develops a substantially different product, such as:
- Extended-release pentazocine;
- A modified-release opioid antagonist system;
- A new abuse-deterrent matrix;
- A sublingual, buccal, transdermal, or injectable dosage form;
- A combination with a different opioid-antagonist ratio;
- A pediatric or geriatric formulation with distinct delivery characteristics.
Those products would require separate FDA regulatory analysis and could carry new intellectual-property rights. They should not be treated as protection for the established immediate-release combination.
What is the Orange Book status of Talwin NX?
The FDA Orange Book is the principal U.S. source for determining whether a reference-listed drug has approved therapeutic-equivalence entries, patent listings, and regulatory exclusivity information.[4]
For an older product such as Talwin NX, Orange Book analysis should focus on:
- Whether the reference listed drug remains active.
- Whether an approved generic product has a therapeutically equivalent rating.
- Whether any current patent or exclusivity listing remains.
- Whether the product has been discontinued for commercial reasons or withdrawn for safety or efficacy reasons.
- Whether an ANDA applicant has a current approval or tentative approval.
A commercial discontinuation is not the same as an FDA determination that a product was withdrawn for safety or effectiveness. This distinction affects whether an ANDA can rely on the reference product and whether the reference product remains eligible for certain regulatory purposes.[4]
Because Orange Book entries can change, current product-specific status should be taken from the latest FDA database record rather than from historical labels or older pharmaceutical directories.
How many patents cover the combination?
The commercially important answer is zero known active composition or core formulation patents for the legacy product. Historical patents may appear in patent databases, but expired patents do not block generic entry.
A new entrant could still face non-patent barriers:
| Barrier |
Impact |
| DEA manufacturing quotas |
Can restrict active-ingredient and finished-dose supply |
| Controlled-substance registration |
Requires compliance by manufacturers, wholesalers, and pharmacies |
| API availability |
Pentazocine supply may be narrower than commodity analgesics |
| FDA quality requirements |
Small-volume products can have high per-unit compliance costs |
| Market withdrawals |
Limited suppliers can create temporary shortages |
| Pharmacist substitution rules |
Depend on therapeutic-equivalence ratings and state law |
| Opioid risk controls |
Raise ongoing compliance and pharmacovigilance expenses |
Which companies are challenging the product?
The market is more likely to involve generic substitution than high-profile patent litigation. Publicly visible Paragraph IV challenges are not a central feature of this mature product category because the principal patent barriers expired many years ago.
What is the Paragraph IV risk?
Paragraph IV litigation is generally used when an ANDA applicant alleges that a listed patent is invalid, unenforceable, or not infringed. For an old immediate-release pentazocine-naloxone product, the expected Paragraph IV risk is low because:
- Core patents are expired;
- Any remaining listings would likely be narrow or administrative;
- The economic value of litigation is limited;
- Generic entry is more likely to depend on ANDA approval and supply economics.
The more relevant litigation risks are product liability, controlled-substance compliance, manufacturing quality, labeling, and distribution disputes.
What patent litigation affects naloxone-pentazocine?
No major active U.S. patent litigation is generally associated with the legacy combination. Any current dispute would more likely concern:
- Manufacturing contracts;
- Product liability;
- False or misleading promotional claims;
- Controlled-substance distribution;
- Quality defects;
- Trademark rights;
- Generic product approval or substitution.
The absence of major patent litigation reflects the product’s age and limited revenue opportunity, not the absence of regulatory obligations.
How strong is the patent estate for naloxone-pentazocine?
The patent estate is weak for the established product and potentially stronger only for redesigned delivery systems.
| Patent-estate factor |
Assessment |
| Core molecule protection |
None of practical commercial value |
| Combination protection |
Expired or exhausted |
| Formulation protection |
Limited for the legacy tablet |
| Method-of-use protection |
Limited and unlikely to block ordinary generic use |
| Manufacturing protection |
Potentially valuable as know-how, not usually exclusionary patent protection |
| Freedom-to-operate risk |
Low for the basic immediate-release tablet |
| Ability to support premium pricing |
Low |
| Defensive value |
Limited |
A company seeking to relaunch the product would need to compete on reliable supply, channel access, contract pricing, and regulatory execution rather than patent-based differentiation.
What are the market dynamics for the combination?
The market is mature and structurally constrained.
Demand drivers
Demand can persist in several settings:
- Patients requiring oral opioid analgesia;
- Prescribers seeking a mixed agonist-antagonist opioid;
- Hospitals or managed-care systems with established formularies;
- Patients with prior experience using pentazocine;
- Periods when alternative opioid products face shortages.
Pentazocine may have a differentiated pharmacologic profile, but that profile has limited commercial value because clinicians have access to many alternative analgesics.
Demand pressures
The principal volume pressures are:
- Reduction in opioid prescribing;
- Preference for non-opioid pain treatment;
- Generic competition;
- State prescription-monitoring requirements;
- Opioid stewardship programs;
- Formulary substitution;
- Limited use of pentazocine in contemporary pain practice;
- Concern about dysphoria and psychotomimetic effects associated with pentazocine;
- Availability of other immediate-release opioid products.
The naloxone component provides an abuse-deterrence rationale but does not create the premium pricing associated with a novel abuse-deterrent technology.
What is the financial trajectory of naloxone-pentazocine?
The financial trajectory is likely characterized by declining or flat unit demand, low pricing power, intermittent supply economics, and limited strategic investment.
Public company filings generally do not report revenue for pentazocine-naloxone as a standalone product. Revenue may be included within a broader generic pharmaceuticals, hospital products, or mature brands segment. As a result, precise historical sales, gross margin, and market-share estimates cannot be derived reliably from company-level disclosures.
Financial profile
| Metric |
Expected trajectory |
| Revenue growth |
Flat to declining |
| Pricing power |
Low |
| Gross margin |
Vulnerable to small scale and compliance costs |
| Market size |
Niche within the opioid analgesic market |
| Generic erosion |
Already largely realized |
| Promotional spending |
Low |
| Manufacturing economics |
Sensitive to batch size and API cost |
| Supply risk |
Higher than for common non-controlled analgesics |
| Licensing value |
Low for the legacy product |
| Litigation value |
Limited patent value; regulatory risk remains |
A supplier may achieve acceptable returns if it has existing controlled-substance infrastructure and can produce the product as part of a broader portfolio. A standalone investment in the product is less attractive because fixed regulatory, quality, and distribution costs can consume margins at low volumes.
How does the product compare with other opioid analgesics?
| Product category |
Competitive position versus pentazocine-naloxone |
| Hydrocodone-acetaminophen |
Greater prescribing familiarity and broader generic supply |
| Oxycodone products |
Stronger historical demand but greater regulatory scrutiny |
| Tramadol |
Often perceived as a lower-intensity alternative, although still an opioid |
| Buprenorphine products |
Stronger role in opioid use disorder and certain pain indications |
| Non-opioid analgesics |
Lower abuse risk and preferred for many chronic-pain patients |
| Abuse-deterrent opioids |
Potentially stronger IP and differentiation, but higher cost |
| Standalone naloxone |
Different clinical purpose: overdose reversal, not analgesia |
Pentazocine-naloxone has a narrow position between conventional immediate-release opioids and abuse-deterrent formulations. Its low price supports access but limits commercial differentiation.
What generic launch scenarios exist?
Scenario 1: Continued low-volume generic supply
This is the most probable outcome. One or more manufacturers maintain the product for institutional, retail, or contract customers. Revenue remains modest, with occasional price increases during supply disruptions.
Scenario 2: Supplier exit and intermittent shortage
Low demand, controlled-substance compliance costs, API constraints, or manufacturing problems could lead to product withdrawal. A remaining supplier could gain temporary share without achieving durable pricing power.
Scenario 3: Portfolio-based relaunch
A generic manufacturer with existing opioid infrastructure could relaunch or expand the product as part of a mature-products portfolio. The investment case would depend on manufacturing efficiency and distribution contracts rather than patent protection.
Scenario 4: Reformulated product
A reformulated product with a new delivery system or abuse-deterrent profile could create new IP value. It would require clinical, CMC, regulatory, and commercial investment that is disproportionate to the legacy product’s current market size unless a clear unmet need is demonstrated.
What licensing deals are relevant?
No major recent licensing transaction is generally associated with the legacy pentazocine-naloxone combination. Licensing value is constrained by:
- Expired core patents;
- Small addressable market;
- Generic pricing;
- Limited clinical differentiation;
- Controlled-substance obligations;
- Lack of publicly reported product-level revenue.
Potential transaction value would reside in a broader portfolio, manufacturing platform, geographic rights, or supply agreement rather than in the molecule combination alone.
What is the geographic coverage?
The combination has its strongest historical relevance in the United States, where Talwin NX and related products have been marketed. Availability outside the United States varies by country because:
- Pentazocine scheduling differs by jurisdiction;
- Naloxone combination products may not have equivalent approvals;
- Local opioid formularies differ;
- Generic registration may be absent;
- National tender systems can determine supply;
- Import and controlled-substance rules may restrict distribution.
Global commercial expansion would face limited upside unless the product addresses a specific local supply or formulary need.
What manufacturing and intellectual-property barriers exist?
The principal barriers are operational rather than patent-based.
A manufacturer must control:
- Pentazocine API sourcing;
- Naloxone API sourcing;
- Content uniformity at the low naloxone dose;
- Controlled-substance inventory;
- Batch records and diversion controls;
- Stability and packaging;
- FDA inspection readiness;
- Pharmacovigilance;
- Distribution reporting and suspicious-order monitoring.
The 50 mg/0.5 mg ratio also creates manufacturing requirements around low-dose naloxone uniformity. These requirements may be manageable for an established tablet manufacturer but costly for a new entrant without controlled-substance infrastructure.
Key Takeaways
- Naloxone hydrochloride and pentazocine hydrochloride is a mature oral opioid combination, commonly associated with Talwin NX.
- Core composition, combination, and legacy formulation patents have no meaningful remaining commercial life.
- Paragraph IV and patent-litigation risk are low compared with newer branded drugs.
- The FDA and DEA compliance burden remains significant despite limited patent protection.
- Public disclosures do not support a reliable standalone revenue forecast.
- The financial profile is mature, niche, and likely flat to declining.
- Commercial success depends on supply reliability, manufacturing scale, formulary access, and controlled-substance compliance.
- New value would require a differentiated formulation or delivery system with new regulatory and patent protection.
- The product is less attractive as a standalone licensing or investment target than as part of a broader mature-drug portfolio.
FAQs
Is naloxone-pentazocine the same as Narcan?
No. Naloxone-pentazocine is an oral analgesic combination. Narcan is a naloxone product used to reverse opioid overdose. The products have different indications, dosage forms, strengths, and regulatory purposes.
Is pentazocine-naloxone an abuse-deterrent opioid?
It is designed to reduce the attractiveness of injection misuse through the inclusion of naloxone. It should not automatically be classified as an FDA abuse-deterrent formulation with labeling under the FDA’s current abuse-deterrent opioid framework.
Can a generic company obtain meaningful pricing power for the product?
Usually not. Pricing power would most likely arise from a temporary shortage, limited competition, or contract concentration. Expired patents and low clinical differentiation limit durable premium pricing.
Does the combination have biosimilar risk?
No. Biosimilar regulation applies to biologic products. Pentazocine-naloxone is a chemically synthesized small-molecule drug and faces generic, not biosimilar, competition.
Is the product a strong candidate for pharmaceutical acquisition?
As a standalone asset, it is generally a weak acquisition candidate because the product is mature, patent-exposed to generic competition, and unlikely to generate substantial growth. Its value may increase when combined with manufacturing capacity, an established opioid portfolio, or a broader contract-supply arrangement.
References
- U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling. https://www.fda.gov
- U.S. Food and Drug Administration. (n.d.). Talwin NX prescribing information. FDA-approved product labeling.
- U.S. Drug Enforcement Administration. (n.d.). Controlled substances schedules. https://www.dea.gov
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda
